Phase 1 Study of Antigen-specific Cytotoxic T Lymphocytes Induced by Dendritic Cells Infected by Recombinant Adeno-associated Virus With MUC1 Gene(MUC1-gene-DC-CTL) or Directly Pulsed by MUC1 Peptide(MUC1-peptide-DC-CTL) in Gastric Cancer.

Trial Profile

Phase 1 Study of Antigen-specific Cytotoxic T Lymphocytes Induced by Dendritic Cells Infected by Recombinant Adeno-associated Virus With MUC1 Gene(MUC1-gene-DC-CTL) or Directly Pulsed by MUC1 Peptide(MUC1-peptide-DC-CTL) in Gastric Cancer.

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 30 Dec 2016

At a glance

  • Drugs MUC1 gene DC-CTL (Primary) ; MUC1 peptide DC-CTL (Primary)
  • Indications Gastric cancer
  • Focus Therapeutic Use
  • Sponsors Beijing Doing Biomedical
  • Most Recent Events

    • 27 Dec 2016 Planned End Date changed from 1 Jun 2018 to 1 Aug 2019.
    • 27 Dec 2016 Planned primary completion date changed from 1 Dec 2017 to 1 Mar 2019.
    • 27 Dec 2016 Planned initiation date changed from 1 Dec 2015 to 1 Mar 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top